



Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Junichi Takada¹ · Rajani Dinavahi² · Akimitsu Miyauchi³ · Etsuro Hamaya⁴ · Toshiyasu Hirama⁴ · Cesar Libanati⁵ · Yoichi Nakamura⁴ · Cassandra E. Milmont² · Andreas Grauer²

Published online: 20 March 2020

© The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2020

Correction to: Journal of Bone and Mineral Metabolism
<https://doi.org/10.1007/s00774-019-01057-1>

In the original publication of the article, the last row of Table 1 was published incorrectly as “Serum P1NP (μmol/L), median (IQR)^b: Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)”. The correct row should be read as “Serum P1NP (μg/L), median (IQR)^b: Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)”.

In addition, the corresponding footnote for the marker ^b should read as “^bPre-menopausal reference range for serum P1NP is 14.9–68.8 μg/L.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00774-019-01057-1>.

✉ Junichi Takada
jtakada@kitago-ortho.com

¹ Kitago Orthopedic Clinic, Hokkaido, Japan

² Amgen Inc., Thousand Oaks, CA, USA

³ Miyauchi Medical Center, Osaka, Japan

⁴ Amgen Astellas BioPharma K.K., Tokyo, Japan

⁵ UCB Pharma, Brussels, Belgium